Clinical Trial Update: Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating an anti-PD-1 antibody in combination with anlotinib for endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Anti-PD-1 antibody

Snippet

Sponsor: Sun Yat-sen University | Conditions: Endometrial Cancer | Phase 1, Phase 2 | Status: UNKNOWN